Search the Newsreel

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

This article analyzes Allogene Therapeutics (NASDAQ:ALLO) and suggests it is in a strong financial position to invest in growth. It likely reviews the company's financial health, market performance, or strategic advantages that enable such investments. The analysis indicates a positive outlook regarding the company's …

Boyaa Interactive’s Core Gaming Revenue Grows, But Digital Asset Losses Drive Heavy Interim Deficit

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $29 from $28, maintaining a "buy" rating and projecting a 39.8% upside. Despite a recent quarterly loss of $0.41 per share and revenue below estimates, analyst sentiment remains largely positive, with a …

H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated a Buy rating for Seaport Therapeutics (NASDAQ:SPTX) with a $50.00 price target. The firm highlighted that the positive clinical data from a competitor's candidate could reduce competitive pressure for Seaport's GlyphAllo, and their non-hallucinogenic psychedelic candidate, Glyph2BLSD, could offer a …

Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Seaport Therapeutics (SPTX), setting a $50 price target, which suggests a 104.75% upside. Despite this, analyst sentiment remains mixed, leading to a consensus "Hold" rating with an average target of $38.40. The company recently reported a …

Federal Signal: Solid Fundamentals Keep The Buy Case Intact (NYSE:FSS)

FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival

Rein Therapeutics (NASDAQ: RNTX) announced that its lead candidate, LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis (IPF), has received Fast Track designation from the U.S. FDA. This designation aims to expedite development and review for serious conditions with unmet medical needs. The company …

Jerash Holdings to Present at Lake Street's 10th Annual Best Ideas Growth Conference, September 10

FAIRFIELD, NJ / ACCESS Newswire / August 20, 2026 / Jerash Holdings (US), Inc. (Nasdaq:JRSH), which manufactures and exports custom, ready-made, sportswear and outerwear in Jordan for leading global brands, today announced that Gilbert Lee, its chief financial officer, will participate at Lake Street …

General Dynamics stock holds steady as new Canadian weapons contract underpins Q2 2026 earnings beat

Motor & General Finance Ltd. Revenue Breakdown – NSE:MOTOGENFIN

Generac plans $250M factory expansion as AI fuels energy demand

[Industrial Generac generator on pad] J. Michael Jones/iStock Editorial via Getty Images Generac Holdings (GNRC [https://seekingalpha.com/symbol/GNRC]), a company best known for backup generators used during household power outages, is finding a major new source of growth in the artificial-intelligence boom. The Wisconsin-based manufacturer plans …

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright

HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company …

Atomera Provides First Quarter 2021 Results

Atomera Incorporated announced its financial results for the first quarter ended March 31, 2021, reporting revenue of $400,000 and a net loss of $3.6 million. The company achieved a major milestone by delivering its MST film recipe to a JDA customer, granting its first …

Radiopharm advances RAD202 trial to higher dose level By Investing.com

Radiopharm Theranostics has received approval from its Data Safety and Monitoring Committee to increase the dose level of its RAD202 radiotherapeutic to 180mCi in a Phase 1 clinical trial. The trial, named HEAT, is evaluating 177Lu-RAD202 in patients with HER2-positive advanced solid tumors. This …

TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD

This article provides a revenue breakdown for TherapeuticsMD, Inc. (NASDAQ: TXMD), highlighting that the greatest contribution to its revenue came from the United States, accounting for $1.79 million USD last year and $1.12 million USD the year prior. The data is presented through TradingView, …

Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest Trading - Profit Growth Outlook

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response

Q4 EPS Estimates for General Motors Lifted by Zacks Research

Zacks Research has increased its Q4 2026 EPS estimate for General Motors (GM) to $2.56, up from $2.52, while analysts maintain a "Moderate Buy" rating with a $101.41 average price target. GM recently surpassed quarterly expectations with $3.57 EPS and $48.03 billion in revenue, …

Enterprise value to revenue forward of Hightide Therapeutics Inc – HKEX:2511

UBS raises Iovance Biotherapeutics stock price target on revenue beat

The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920

PTC Therapeutics recently discussed the positive regulatory progress of ST-920, supported by Phase 1/2 STAAR data showing significant renal benefits and a favorable safety profile. This development could reshape the company's investment narrative and pipeline, diversifying beyond its current commercial base. While PTC Therapeutics …

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in the life sciences sector, with a strong background in scaling organizations through growth and preparing for commercialization. His appointment comes as …

Equities Analysts Set Expectations for RNTX FY2026 Earnings

HC Wainwright has updated its FY2026 earnings forecast for Rein Therapeutics (NASDAQ:RNTX), narrowing the projected loss per share to $0.47 from $0.53 and maintaining a "Buy" rating. This adjustment follows Rein Therapeutics' reported quarterly loss of $0.10 per share, which significantly beat analyst expectations. …

Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM

Lisanti Capital Growth LLC acquired a new position of 20,825 shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) valued at approximately $5.1 million during the second quarter. This move is part of broader institutional investment, with BlackRock also establishing a significant new position, bringing total institutional …

Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research

Zacks Research downgraded Gyre Therapeutics (NASDAQ:GYRE) from a "hold" to a "strong sell" rating, with other firms also issuing negative ratings, though the overall analyst consensus remains "hold" with a $17 target price. The company reported a quarterly loss of $0.12 per share, missing …

Teradyne (NASDAQ:TER): An Affordable Growth Play with Strong Fundamentals

Inflows Into Money Market Funds Have Been Driving Most of Federated's Improved Results

Federated's improved results are largely driven by inflows into money market funds, according to a Morningstar analyst note. Despite this, the company experienced outflows in Q2, and its shares remain slightly overvalued. The broader asset management industry faces challenges from passive investing and the …

NWK Group Inc. Acquires Shares of 1,658 Casey's General Stores, Inc. $CASY

NWK Group Inc. has acquired a new position in Casey's General Stores, purchasing 1,658 shares valued at approximately $1.32 million. Institutional investors now own 85.63% of the company, which recently reported strong quarterly earnings of $4.37 per share, exceeding estimates, and increased its quarterly …

DoubleDown Interactive Co., Ltd. - American Depository Shares Revenue Breakdown – NASDAQ:DDI

Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?

Halozyme Therapeutics (HALO) recently elected Dannielle Appelhans to its Board of Directors, following strong share price returns, increased revenue, and ongoing buybacks. While analysts generally view HALO as 20.7% overvalued with a fair value of $86.89, a Discounted Cash Flow (DCF) model by Simply …

NextEra Energy, Inc. Revenue Breakdown – MUN:FP3

This article provides a revenue breakdown for NextEra Energy, Inc. (MUN:FP3), detailing its top-performing segment, Florida Power & Light, which generated €15.55 billion last year. The primary geographical contribution came from the United States and Canada, accounting for the entire €23.34 billion revenue.

HC Wainwright Has Bearish Forecast for ELTX Q3 Earnings

Titan Minerals (ASX:TTM) Rallies 21% as Dynasty Gold Scale and Copper Targets Draw Buyers

Accelerant (ARX) Results at a Glance: EPS Clears the Reported Estimate for the Current Session; Market Move: Shares End With Little Net Change on the Day - Profit Inflection Point

International (IGIC) Results Versus Estimates: The EPS Result Is Below Expectation in Latest Trading; Session Move: The Stock Ends Down 0.93% - Profit Warning Alert

Oruka (ORKA) Earnings Snapshot: The Available Earnings Metric Delivers a Miss in the Available Record; Post-Report: Shares Finish 3.00% Down for the Current Session - Earnings Cycle Outlook